United States: Food and Drugs Law

Texas Gov. Greg Abbott on June 22, 2025, signed Senate Bill 25 (SB 25), a law that, among other provisions, requires the following consumer warning labeling on foods containing any of 44 ingredients...

Our notable ruling roundup aims to keep our readers up to date on recent rulings in the food & consumer packaged goods space.

On June 23, HHS Secretary Kennedy and CMS Administrator Dr. Mehmet Oz held a roundtable with health insurance companies to discuss a new pledge to "streamline and improve the prior authorization processes...

CMS recently announced a new model it will be using to pilot the use of artificial intelligence and machine learning in reviewing prior authorizations submitted for certain services...

As public-facing representations, inaccurate Notices of Privacy Pracধces ("NPP") can provide a basis for decepধve or unfair trade pracধces or unfair compeধধon claims, including under the FTC Act.

Over the past two decades, genetic engineering, synthetic biology, and bioinformatics have revolutionised plant science. In this Insight, we explore how recent advances in plant biotechnology...

In a closely watched decision, the Supreme Court has upheld the authority of the U.S. Preventive Services Task Force (Task Force), preserving the Affordable Care Act's (ACA) requirement...

CMS recently announced a new model it will be using to pilot the use of artificial intelligence and machine learning in reviewing prior authorizations submitted for certain services...

Texas Gov. Greg Abbott on June 22, 2025, signed Senate Bill 25 (SB 25), a law that, among other provisions, requires the following consumer warning labeling on foods containing any of 44 ingredients...

In Otsuka Pharmaceutical Co. v. Sandoz, Inc., the Federal Circuit upheld the district court’s determination that the claims at issue were neither obvious nor invalid under the doctrine of obviousness-type double patenting based on a "lead compound" approach to the obviousness determinations.

After the Supreme Court decided that the personalized medicine method claims at issue in Mayo Collaborative Services v. Prometheus Laboratories, Inc. did not satisfy the patent eligibility requirements of 35 USC § 101.

GlaxoSmithKline and Genentech have settled a U.S. lawsuit related to Genentech's Cabilly II (US 6,331,415) and Cabilly III (US 7,923,221) patents.